The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子
基本信息
- 批准号:8548721
- 负责人:
- 金额:$ 215.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-25 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdverse effectsAreaBehaviorBiologicalBiological AssayBiological MarkersBiological ProcessBiostatistics CoreBudgetsCancer CenterCancer DetectionCancer PatientCancer SurvivorCandidate Disease GeneCase-Control StudiesCellsCessation of lifeClinical ManagementClinical ResearchClinical TrialsCollaborationsCombined Modality TherapyComplicationContinuance of lifeCritiquesCyclin-Dependent KinasesDNADentalDetectionDevelopmentDiagnosisDiseaseDisease OutcomeDistant MetastasisDoctor of MedicineDrug resistanceEarly DiagnosisFunctional disorderGenesGeneticGoalsIncidenceIndividualIndolentInstitutionInterventionKnowledgeLifeLong Term SurvivorshipMEKsMalignant NeoplasmsMalignant neoplasm of thyroidMeasuresMolecular AbnormalityMonitorMutationNeoplasm Circulating CellsNeoplasm MetastasisOhioOutcomePainPapillary thyroid carcinomaPartial RemissionPathway interactionsPatientsPenetrancePhase II Clinical TrialsPlayPopulationPredispositionPreventivePropertyProspective StudiesProteomicsPublishingQuality of lifeRadioactive IodineRecommendationRecording of previous eventsRecurrenceReportingReproduction sporesResearchResearch PersonnelResistanceRiskRoleSalivary GlandsStable DiseaseTNFRSF5 geneTaste PerceptionTestingTherapeuticTranscriptTranslational ResearchTranslational Research Working GroupTranslationsUnited StatesUniversitiesUniversity of Texas M D Anderson Cancer CenterUntranslated RNAValidationVertebratesWomanXerostomiabasecancer riskcancer stem cellcareercareer developmentclinical careclinical practiceexperiencegenome wide association studyhuman subject protectionimprovedin vivoinhibitor/antagonistmedullary thyroid carcinomameetingsmenmortalitynovelnovel strategiespatient populationpreventprogramsresponsesurvivorshiptumortumor progression
项目摘要
DESCRIPTION 3
OVERALL CRITIQUE 3
SPORE PROGRAM ORGANIZATION AND CAPABILITIES 6
SCIENTIFIC COLLABORATIONS 8
PROTECTION OF HUMAN SUBJECTS 10
VERTEBRATE ANIMALS 10
SCIENTIFIC REVIEW OFFICER'S NOTES 10
INDIVIDUAL PROJECTS AND CORES 11
PROJECT 1: Low-Penetrance Genes in the Predispositon to Papillary Thyroid Cancer 11
PROJECT 2: Preserving Salivary Gland Function after Radioiodine Therapy
for Thyroid Cancer 15
PROJECT 3: Developing Combination Therapies for Medullary Thyroid Cancer 23
PROJECT 4: Development and Validation of Novel Circulating Medullary Thyroid Cancer Markers 29
CORE A/1: Integrated Clinicopathology and Biorespository Core 34
CORE B/2: Biostatistics Core 38
CORE C/3: Administrative Core 41
DEVELOPMENTAL RESEARCH PROGRAM 43
CAREER DEVELOPMENT PROGRAM 45
COMMITTEE BUDGET RECOMMENDATIONS 48
SPECIAL EMPHASIS PANEL ROSTER
DESCRIPTION (provided by applicant): The primary goal of The Ohio State University / M.D. Anderson Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically "at-risk" individuals allowing for early diagnosis and prediction
of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease. Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide; it s now the 5th most common malignancy in women and 11th most common in men. 2) Thyroid cancer typically takes an indolent course, thus with the increasing incidence there is an ever enlarging population of individuals (-500,000) surviving long term, many of whom suffer from lifelong effects of initial therapy. 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict outcome from disease or response to particular treatments thereby limiting efforts to individualize therapeutic intensity. In order to achieve our goals, this SPORE application proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen t focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients with the following four Projects supported by outstanding Cores: 1) Low-penetrance genes in the predisposition to papillary thyroid carcinoma; 2) Biomarker discovery and personalized intervention of radioiodine induced salivary gland damage in thyroid cancer patients; 3) Developing combination therapies for Medullary Thyroid Cancer; and 4) Development and validation of novel circulating medullary thyroid cancer markers. Through these translational Projects, as well as Career Developmental and Developmental Research Programs, we aim to impact on critical areas of need in thyroid cancer clinical management for all forms of thyroid cancer.
RELEVANCE: Thyroid cancer incidence is rising. Key issues in clinical care related to predictive testing for more aggressive disease, improving survivorship as many patients live for decades after their diagnosis, improving treatment for patients with aggressive forms of thyroid cancer and improving detection and monitoring of metastases This SPORE addresses these critical areas to improve the outcomes of patients with thyroid cancer.
描述 3
总体评论 3
孢子囊组织和能力 6
科学合作 8
人类受试者保护 10
脊椎动物 10
科学审评员注释 10
个人项目和核心 11
项目1: 低外显率基因与甲状腺乳头状癌的易感性 11
项目二: 放射性碘治疗后唾液腺功能的保护
甲状腺癌 15
项目3: 发展甲状腺髓样癌的综合治疗 23
项目4: 新型循环甲状腺髓样癌标志物的开发和验证 29
核心A/1: 综合临床病理学和生物库核心 34
核心B/2: 生物统计学核心 38
核心C/3: 行政核心 41
企业文化 43
职业发展计划 45
委员会的预算建议 48
特别强调小组名册
描述(由申请人提供):俄亥俄州州立大学/医学博士的主要目标。安德森甲状腺癌孢子是改善结果和甲状腺癌患者的生活,通过识别遗传“风险”的个人,允许早期诊断和预测
研究肿瘤行为,开发新的方法来最大限度地减少治疗的副作用,并为进行性转移性疾病开发更好的生物标志物和治疗方案。有几个因素支持将这些努力应用于甲状腺癌的重要性:1)甲状腺癌的发病率在美国和世界范围内以所有恶性肿瘤中最快的速度上升;它现在是女性中第五常见的恶性肿瘤,男性中第11常见。2)甲状腺癌通常采取无痛过程,因此随着发病率的增加,长期存活的个体群体不断扩大(约500,000人),其中许多人遭受初始治疗的终身影响。3)对于患有更具侵袭性形式的甲状腺癌(例如髓样癌(MTC))的患者,不存在准确预测疾病结果或对特定治疗的反应的治愈性疗法或生物标志物,从而限制了个体化治疗强度的努力。为了实现我们的目标,此SPORE应用程序建议支持来自该领域两个具有合作临床试验历史的领先机构的经验丰富的研究人员组成的多机构团队。我们选择了以下四个项目来关注甲状腺癌患者快速转化为临床实践的关键领域:1)甲状腺乳头状癌易感基因的低表达; 2)甲状腺癌患者放射性碘诱导唾液腺损伤的生物标志物发现和个性化干预; 3)甲状腺髓样癌的联合治疗;和4)新的循环甲状腺髓样癌标志物的开发和验证。通过这些转化项目,以及职业发展和发展研究计划,我们的目标是影响甲状腺癌临床管理的关键领域。
相关性:甲状腺癌的发病率正在上升。临床护理中的关键问题涉及对更具侵袭性疾病的预测性检测,提高生存率,因为许多患者在诊断后存活数十年,改善侵袭性甲状腺癌患者的治疗,改善转移的检测和监测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew D Ringel其他文献
Matthew D Ringel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew D Ringel', 18)}}的其他基金
RCAN 1.4 metastasis suppressor in thyroid cancer
RCAN 1.4 甲状腺癌转移抑制因子
- 批准号:
9973560 - 财政年份:2020
- 资助金额:
$ 215.05万 - 项目类别:
RCAN 1.4 metastasis suppressor in thyroid cancer
RCAN 1.4 甲状腺癌转移抑制因子
- 批准号:
10604328 - 财政年份:2020
- 资助金额:
$ 215.05万 - 项目类别:
RCAN 1.4 metastasis suppressor in thyroid cancer
RCAN 1.4 甲状腺癌转移抑制因子
- 批准号:
10400004 - 财政年份:2020
- 资助金额:
$ 215.05万 - 项目类别:
Role of p21-activated kinases in thyroid cancer
p21 激活激酶在甲状腺癌中的作用
- 批准号:
10377551 - 财政年份:2018
- 资助金额:
$ 215.05万 - 项目类别:
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health
俄勒冈州立大学临床和转化科学中心:推进当今的发现以改善健康
- 批准号:
10414809 - 财政年份:2018
- 资助金额:
$ 215.05万 - 项目类别:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子
- 批准号:
8741949 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
Developing Combination Therapies for Medullary Thyroid Cancer
开发甲状腺髓样癌的联合疗法
- 批准号:
8588547 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
Integrated Clinicopathology and Biorespository Core
综合临床病理学和生物仓库核心
- 批准号:
8588551 - 财政年份:2013
- 资助金额:
$ 215.05万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 215.05万 - 项目类别:
Research Grant